Phoenix Meds Inc. provides administrative sourcing coordination for licensed U.S. healthcare organizations. We assist with professional credential verification, documentation, and communication between clinics and independent pharmaceutical sources. Phoenix Meds is not a pharmacy, wholesaler, distributor, or medical practice and does not independently prescribe, manufacture, compound, dispense, or ship medications.
Before evaluating a pharmaceutical source, clinics may need answers about the organizations involved, the information available, and the scope of a supplier’s authorization. Phoenix Meds helps bring these details into focus through an organized approach shaped by industry experience and an understanding of the sourcing process.
A supplier’s license is an important starting point, but it does not establish that every product or transaction is permitted. Clinics must also consider the type of facility involved and the requirements applicable to its activities.
Traditional compounding pharmacies, FDA-registered 503B outsourcing facilities, and pharmaceutical wholesalers operate under different regulatory frameworks. For example, registration as a 503B outsourcing facility does not mean the FDA has approved its compounded drugs or determined that the facility complies with every applicable requirement.
For clinics, a meaningful review looks beyond a registration number. The specific preparation, intended activity, and applicable federal and state requirements all matter when evaluating a potential pharmaceutical source.
Phoenix Meds Inc. was founded by Alfred Lamoureux, who brings more than 20 years of experience in pharmaceutical sourcing and healthcare operations. His industry background shapes our practical approach to working with clinics and independent pharmaceutical organizations. Our Working Principles:
a) Professional Credentials: We assist with requests for relevant licensing information, facility registration details, and supporting records.
b) Organized Follow-Ups: We help track outstanding inquiries and facilitate responses between participating parties.
c) Clear Responsibilities: Clinical decisions, product quality assurance, and regulated fulfillment activities remain with the appropriately authorized organizations.
We support clinics and medical providers in sourcing high-demand peptides and injectable medications across key therapeutic and research domains.
Our network focuses on compounds relevant to:
Product availability and fulfillment eligibility are determined by the independently authorized supplier, subject to applicable federal and state requirements. Phoenix Meds provides administrative coordination and does not guarantee product availability.
Clinics within our network commonly request peptides across a range of research and clinical interest areas, including:
Thymosin Beta-4, BPC-157, KPV, GHK-Cu
AOD-9604, CJC-1295, Ipamorelin, MOTS-C
Semax, Selank, DSIP (Emideltide)
Thymosin Alpha-1, Epitalon, LL-37
GHRP-2, GHRP-6, Kisspeptin-10, PEG-MGF, Melanotan II
These categorizations reflect areas of clinical and research interest and do not imply approved therapeutic indications.
We support the coordination and sourcing of Tesamorelin for clinics and licensed providers operating within approved clinical or investigational frameworks. This compound is commonly referenced in metabolic and endocrine-related research and treatment contexts.
Access is subject to appropriate clinical authorization and jurisdictional requirements.
Phoenix Meds assists licensed U.S. healthcare organizations with professional credential information, supplier documentation requests, and follow-up communication. Our services are administrative and do not include prescribing, manufacturing, selling, dispensing, or shipping medications.
A professional license or facility registration is an important starting point, but it does not establish that every product or transaction is permitted. Clinics must consider the relevant authorization, the type of facility involved, and any requirements specific to the preparation or activity.
No. We may review publicly available licensing information and help organize supplier-provided records, but this does not constitute regulatory certification or a guarantee of product quality. Each organization remains responsible for its own applicable obligations.
Office use generally refers to compounded medications intended for administration within a healthcare setting rather than dispensing directly to an identified patient. Whether a preparation may be supplied for this purpose depends on the applicable federal and state requirements and the compounding framework involved.
No. DEA registration requirements generally apply to activities involving controlled substances. Other professional licensing or authorization requirements may still apply, depending on the medication, practitioner, activity, and jurisdiction.
Section 503A generally addresses qualifying compounding by licensed pharmacists or physicians based on patient-specific prescriptions, with limited anticipatory compounding permitted under statutory conditions.
Section 503B establishes a separate framework for FDA-registered outsourcing facilities. These facilities are subject to current good manufacturing practice requirements and may compound medications without individual patient prescriptions when applicable conditions are satisfied.
Compounded drugs under either framework are not FDA-approved.
The independent organization performing dispensing, distribution, or fulfillment is responsible for meeting the requirements applicable to that activity. Whether a particular shipment is permitted depends on the product, the entities involved, and applicable federal and state law. Phoenix Meds does not independently package or ship medications.
Start with professional verification. Once eligibility is confirmed, Phoenix Meds can help organize your sourcing and coordination needs.
Your order has been placed successfully.
We have sent an order confirmation email to
info@example.com